Aleksandr B Shek

TL;DR: Assessment of current identification and management of children and adolescents younger than 18 years with HeFH found increased availability and use of LDL-C measurements in the first few years of life could help reduce the current gap between prevalence and detection, enabling increased use of combination LLM to reach recommended LDL-C targets early in life.

TL;DR: The addition of metformin to ongoing rosuvastatin therapy did not significantly affect serum lipid levels, but stabilized the level of circulating PCSK9, compared with the group without meetformin treatment.

TL;DR: Improvement of early diagnosis of FH, including genetic confirmation, and preventional high-intensity statin therapy or a combination of statins with ezetimibe to achieve the target level of LDL-C, is the closest tactical objective for prevention of MACE within the Uzbek population.

TL;DR: In a considerable proportion of ethnic Uzbek patients with CAD and simVastatin intolerance symptoms, serious side effects when switching to a starting dose of rosuvastatin were not observed, and it should be noted that in most cases this phenomenon was observed among the carriers of *3/*3 genotype of the CYP3A5 (6986A> G) gene.